- Global Pharma News & Resources

Myeloma UK London Paris Ride 2020 Launch

Myeloma UK welcomes global participation for London Paris Ride 2020

National Blood cancer charity Myeloma UK have launched their 2020 London Paris Ride to help raise crucial funds for myeloma research. The first ride began in 2016 and today Myeloma UK are pleased to welcome supporters from across the globe to sign up to this unique pro-ride experience from today.

The Myeloma UK London Paris Ride 2020 will take place between Wednesday 16 – Sunday 20 September and aims to raise as much money as possible to ensure that myeloma patients get access to the right treatment at the right time, and to improve standards of treatment and care.

Riding in a peloton, participants will be flanked by motorcycle outriders, fully backed up by mechanics, remedied by sports physios and propelled forward by their very own support crew, making this the ultimate pro-ride experience.  

Rolling road closures ensure rider safely without stopping for traffic lights or junctions, and there are different speed groups led by experienced Ride Captains. After four days in the saddle and 500km on the road, participants will enjoy the rare and privileged finale of cycling on traffic-free roads into Paris as  one huge peloton, riding around the Arc de Triomphe and then on to finish near the Eiffel Tower.  

Riders are encouraged to sign up now for the early bird deposit of £249 available until 29 February 2020.

Speaking ahead of the 2020 launch, Marc Gordon, Chairman, Myeloma UK said:

“The London Paris Ride is an extremely rewarding experience and creates a unique sense of solidarity, with patients, carers and healthcare professionals all coming together from around the world to help make myeloma history. We encourage anyone to sign up to our ride no matter where you are situated in the world. Riders participating in the event will be raising money to help Myeloma UK support patients and their families through their myeloma diagnosis as well as funding world-leading genetics research to develop and discover new tailored treatments. By signing up to the ride you will be making a real difference to thousands of people living with myeloma.” 

Previous 2019 Ride participant, Brad Moning, from the USA said:

“Last year, riders from the UK and US came together as cycling comrades to conquer the challenges of the London to Paris Ride.  This year, Myeloma UK are once again extending the invitation to the rest of the world – you can join them as one global family and help raise money to support world-leading research into the causes and treatment of myeloma. These are very exciting and promising times for myeloma research and progress seems to be advancing exponentially. Let’s take it across the finish line and make myeloma history.”

Myeloma, also known as multiple myeloma, is a blood cancer arising from plasma cells. At any one time there are around 17,500 people living with myeloma in the UK. It accounts for 15 per cent of blood cancers, and two per cent of all cancers. Myeloma mainly affects those over the age of 65, however it has been diagnosed in people as young as 20. Whilst there is currently no cure for myeloma, it is treatable.

Participants can find out more information and sign up for the 2020 Ride through the Myeloma UK Ride website  

About Myeloma UK

Myeloma UK is the only organisation in the UK dealing exclusively with myeloma – our ultimate goal is to find a cure- make myeloma history

We are dedicated to ensuring that patients get access to the right treatment at the right time, and to improving standards of treatment and care through research, education and awareness raising, particularly to improve earlier diagnosis

Our organisation also provides a range of information and support services to patients, family and friends to help deal with a diagnosis of myeloma and these are of crucial help to patients and their families

Myeloma UK receives no Government funding and relies almost entirely on voluntary donations and fundraising.

To find out more visit:, or follow us on Twitter: /MyelomaUK and Facebook: /MyelomaUK.

About myeloma

Myeloma is the third most common form of blood cancer. It originates in the bone marrow and currently affects around 17,500 people in the UK.

On average 15 people a day are diagnosed within the UK.

Whilst treatable, myeloma is not yet curable.

Treatment aims to control the myeloma, relieve symptoms and improve quality of life. It generally leads to periods of remission but patients inevitably relapse requiring further treatment.

This is why it is vital that we invest in research, and support access to the best treatment and care for myeloma patients.

Myeloma UK, 22 Logie Mill, Beaverbank Business Park, Edinburgh, Scotland, EH7 4HG, United Kingdom

Editor Details

  • Company:
    • Myeloma UK
  • Name:
    • Myeloma UK
Last Updated: 22-Jan-2020